CRVS241220P7000
- 1.25
- -0.10-7.41%
Corvus Pharmaceuticals Newsroom
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
Attackers Targeting VPNs Account for 28.7 Percent of Ransomware Incidents in Q3 According to Corvus Insurance Cyber Threat Report
US pharmaceutical stocks plummet, has the market overreacted to Little Kennedy?
Source: Analysis from Wall Street News states that even if Kennedy is confirmed as the Secretary of Health in the usa, he may not be able to "make a big impact". First, there may be divisions within Trump's team; secondly, it is uncertain whether Kennedy has the authority to appoint leaders of departments like the FDA; finally, Trump may appoint individuals with industry backgrounds as FDA commissioners, directing Kennedy's attention to focus on nutrition rather than pharmaceutical approvals. The famous "anti-vaccine pioneer" and advocate for healthy eating, the new government-nominated Secretary of Health Robert Kennedy, is dining with the loyal "fast food enthusiast" Trump, who promotes rapid vaccine development.
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Insider Buyers At Corvus Pharmaceuticals Sitting On US$3.9m Profit
Daily options tracking | Electric car companies are about to face a "storm?" Large options trades still bet on Tesla's rise; the audit turmoil continues! Super micro computer put trade surges.
Disney's performance exceeded expectations, with strong growth in its streaming business, surging over 6% overnight. Call options saw a rush in buying, accounting for 70% of the trading volume, with the 115-dollar strike price call options expiring today being the most traded, totaling over 0.0261 million contracts.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $13 to $24
An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Corvus Pharma Analyst Ratings
Express News | Corvus Pharmaceuticals : Oppenheimer Raises Target Price to $14 From $8
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript Summary
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Corvus Pharmaceuticals GAAP EPS of -$0.60 Misses by $0.48
Corvus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Corvus Pharmaceuticals | 8-K: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Corvus Pharmaceuticals 3Q Loss/Shr 60c >CRVS